Schizophrenia Clinical Trials in Austin
View 14 new treatments for Schizophrenia in Austin, TX, and nearby areas, such as Round Rock. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
KarXT for Schizophrenia
Karuna Clinic, Austin + 1 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Ronald Marcus, MD
Study Director
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Austin + 1 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Austin + 1 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Medical Director
Study Director
KarXT for Schizophrenia
Karuna Clinic, Austin + 3 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Austin + 1 more
This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Valbenazine for Schizophrenia
Neurocrine Clinic, Austin + 1 more
The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Development Lead
Study Director
Cariprazine for Pediatric Schizophrenia
AbbVie Clinic, Austin + 1 more
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
MK-8189 for Schizophrenia
Merck Sharp & Dohme Clinic, Austin + 1 more
This trial tests the effectiveness and safety of a medication called MK-8189 in adults with acute schizophrenia. The study compares different doses of the medication to see if it can better reduce symptoms. The goal is to find out if MK-8189 can help improve the condition of these patients.Show More
Recruiting
Phase 2
Est. 4 - 6 Weeks
Medical Director
Study Director
Emraclidine for Schizophrenia
Cerevel Clinic, Austin + 1 more
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Recruiting
No Placebo Trial
Phase 2
Est. 5 - 8 Weeks
Erica Koenig, PhD
Study Director
Emraclidine for Schizophrenia
Cerevel Clinic, Austin + 1 more
This trial is testing a new medication called Emraclidine, given in two different doses daily. It aims to help people with schizophrenia who are having severe symptom flare-ups. The medication works by targeting specific parts of the brain to reduce symptoms like hallucinations and delusions.Show More
Waitlist
Phase 2
Est. 6 - 12 Weeks
Erica Koenig, PhD
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions